Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

+3.34 (+0.37%)
(As of 04/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
351,366 shs
Average Volume
424,009 shs
Market Capitalization
$98.80 billion
P/E Ratio
Dividend Yield
Price Target

Regeneron Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
8.5% Upside
$976.41 Price Target
Short Interest
1.29% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.66mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$13.12 M Sold Last Quarter
Proj. Earnings Growth
From $38.80 to $40.36 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.82 out of 5 stars

Medical Sector

242nd out of 910 stocks

Pharmaceutical Preparations Industry

97th out of 422 stocks

REGN stock logo

About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Stock Price History

REGN Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Cantor Fitzgerald Reaffirms Their Hold Rating on Regeneron (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 2.6%
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
20 Analysts


Net Income
$3.95 billion
Pretax Margin


Sales & Book Value

Annual Sales
$13.12 billion
Cash Flow
$43.42 per share
Book Value
$236.63 per share


Free Float
Market Cap
$98.80 billion

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained


Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

  • Regeneron Pharmaceuticals has a diverse product portfolio, including innovative medicines like EYLEA and Dupixent, which have shown significant success in treating various diseases.
  • The company's ongoing research and development efforts demonstrate a commitment to advancing healthcare solutions and potentially introducing new breakthrough treatments.
  • Regeneron's collaboration with other pharmaceutical companies and research institutions enhances its capabilities for developing cutting-edge therapies and expanding its market reach.
  • Recent positive regulatory approvals and clinical trial results have boosted investor confidence in the company's future growth prospects and revenue potential.
  • Despite market fluctuations, Regeneron's stock price has shown resilience and maintained a relatively stable performance, offering investors a sense of security and potential long-term returns.


Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

  • Regeneron Pharmaceuticals faces intense competition in the biopharmaceutical industry, which could impact its market share and profitability over time.
  • The company's heavy reliance on a few key products, such as EYLEA and Dupixent, for a significant portion of its revenue poses a risk in case of unexpected market changes or regulatory challenges.
  • Fluctuations in research and development outcomes or delays in product launches could affect investor sentiment and lead to short-term volatility in the stock price.
  • Regeneron's exposure to regulatory changes, pricing pressures, and intellectual property disputes within the healthcare sector may create uncertainties for investors regarding the company's future financial performance.
  • Investing in biotechnology companies like Regeneron Pharmaceuticals involves inherent risks related to clinical trial failures, patent expirations, and market unpredictability, which could impact investment returns.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to

REGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price target for 2024?

20 brokerages have issued 1 year price objectives for Regeneron Pharmaceuticals' stock. Their REGN share price targets range from $720.00 to $1,189.00. On average, they predict the company's share price to reach $976.41 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2024?

Regeneron Pharmaceuticals' stock was trading at $878.29 at the start of the year. Since then, REGN shares have increased by 2.5% and is now trading at $900.16.
View the best growth stocks for 2024 here

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our REGN earnings forecast

How can I listen to Regeneron Pharmaceuticals' earnings call?

Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings results on Friday, February, 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. The biopharmaceutical company earned $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 17.61% and a net margin of 30.14%. The business's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter last year, the firm earned $10.96 EPS.
Read the conference call transcript

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Global Assets Advisory LLC (0.32%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Perpetual Ltd (0.08%), Raymond James & Associates (0.06%), Allspring Global Investments Holdings LLC (0.05%) and Atwood & Palmer Inc. (0.04%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
This page (NASDAQ:REGN) was last updated on 4/23/2024 by Staff

From Our Partners